What is the optimal serum potassium level in cardiovascular patients?

MacDonald, John Emyr; Struthers, Allan D.

doi:10.1016/j.jacc.2003.06.021

Cited by 285 publications

(260 citation statements)

References 106 publications

Supporting

Mentioning

224

Contrasting

Unclassified

Order By: Relevance

“…Thus, hypokalemia increases risk of ventricular arrhythmia and sudden cardiac death. 23 HF was observed in 16 % of the AMI population in the present study. We also observed a non-significant association between presence of HF and serum potassium levels in AMI group patients.…”

Section: Discussionsupporting

confidence: 51%

Evaluation of prognostic role of serum potassium in patients with Acute Myocardial Infarction: A cross-sectional study from a tertiary hospital in northern India

Neki¹,

Kumar²,

Kaur³

et al. 2017

Int. J. Curr. Res. Biol. Med.

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 51%

Evaluation of prognostic role of serum potassium in patients with Acute Myocardial Infarction: A cross-sectional study from a tertiary hospital in northern India

Neki¹,

Kumar²,

Kaur³

et al. 2017

Int. J. Curr. Res. Biol. Med.

View full text Add to dashboard Cite

show abstract

“…The electrolyte profile showed a dose dependent decrease in potassium levels in serum. A decrease in serum potassium levels has been linked to increased risk of cardiac events, such as arrhythmia, 30 and hypokalemia has also been associated with small cell lung cancers. 31 Magnesium levels were also decreased with the 10 mg/kg and 20 mg/kg doses of Ni nanoparticles.…”

Section: Dpv Injection Of Ni Nanoparticles Induced Liver Injurymentioning

confidence: 99%

Acute toxicity of nickel nanoparticles in rats after intravenous injection

Magaye¹,

Xia²,

Zou³

et al. 2014

IJN

View full text Add to dashboard Cite

This study was carried out to add scientific data in regard to the use of metallic nanoparticles in nanomedicine. The acute toxicity of nickel (Ni) nanoparticles (50 nm), intravenously injected through the dorsal penile vein of Sprague Dawley rats was evaluated in this study. Fourteen days after injection, Ni nanoparticles induced liver and spleen injury, lung inflammation, and caused cardiac toxicity. These results indicate that precautionary measures should be taken with regard to the use of Ni nanoparticles or Ni compounds in nanomedicine.

show abstract

“…Our patients did not reveal hyperkalemic electrocardiographic changes (not shown). It seems beneficial to keep serum K level above 4.5 mEq/l in acute myocardial infarction and heart failure (Macdonald and Struthers 2004). Optimal level of serum K in patients with chronic renal failure treated with AIIA is yet to be determined.…”

Section: Discussionmentioning

confidence: 99%

Losartan, an Angiotensin-II Receptor Antagonist, Retards the Progression of Advanced Renal Insufficiency

Osawa

Nakamura

Shirato

et al. 2006

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Chronic renal disease with elevated level of serum creatinine (Cr) often progresses to end-stage renal disease. Although blockade of the renin-angiotensin system has been shown to slow the progression of chronic renal disease, it remains uncertain whether one could expect such a renoprotective effect even when the treatment is initiated late in the course of renal disease. The purpose of the present study was to examine the effect of losartan, an angiotensin-II receptor antagonist, on the progression of advanced renal insufficiency. We retrospectively analyzed eight hypertensive patients, whose baseline Cr levels exceeded 2.0 mg/dl (2.2-5.5); the subjects included 6 non-diabetic glomerular diseases, 1 diabetic nephropathy and 1 polycystic kidney disease. Losartan was given at the dosage of 25-50 mg/day. Changes in mean blood pressure (MBP) and serum levels of Cr, potassium (K) and uric acid were evaluated after treatment for 24 weeks. Slopes of reciprocal of serum Cr plotted against time (1/sCr slope), which indicate the rate of renal function loss before and after the treatment period, were compared. There was a significant reduction of 1/sCr slope after losartan (−0.004 ± 0.002 dl/mg/week before and −0.001 ± 0.002 dl/mg/week after the treatment, p < 0.05). MBP and serum levels of Cr, K and uric acid were not changed significantly by losartan treatment. However, improvement of 1/sCr slope was correlated to the degree of MBP changes. Based on the available data from 4 patients, proteinuria was decreased in 3 patients. These results suggest that losartan may retard the progression of advanced renal insufficiency. losartan; renoprotection; advanced renal insufficiency

show abstract

What is the optimal serum potassium level in cardiovascular patients?

Cited by 285 publications

References 106 publications

Evaluation of prognostic role of serum potassium in patients with Acute Myocardial Infarction: A cross-sectional study from a tertiary hospital in northern India

Evaluation of prognostic role of serum potassium in patients with Acute Myocardial Infarction: A cross-sectional study from a tertiary hospital in northern India

Acute toxicity of nickel nanoparticles in rats after intravenous injection

Losartan, an Angiotensin-II Receptor Antagonist, Retards the Progression of Advanced Renal Insufficiency

Contact Info

Product

Resources

About